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Abstract
Mastocytosis is a heterogeneous disease characterized by mast cells accumulation in one or more organs. We have reported
that depression is frequent in mastocytosis, but although it was already described, little is known about the prevalence and
features of cognitive impairment. Our objective was to describe the prevalence and features of cognitive impairment in a
large cohort of patients with this rare disease (n=57; mean age=45) and to explore the relations between memory
impairment and depression. Objective memory impairment was evaluated using the 3
rd edition of the Clinical Memory scale
of Wechsler. Depression symptoms were evaluated using the Hamilton Depression Rating Scale. Age and education levels
were controlled for all patients. Patients with mastocytosis presented high levels of cognitive impairment (memory and/or
attention) (n=22; 38.6%). Cognitive impairment was moderate in 59% of the cases, concerned immediate auditory (41%)
and working memory (73%) and was not associated to depression (p$0.717). In conclusion, immediate auditory memory
and attention impairment in mastocytosis are frequent, even in young individuals, and are not consecutive to depression. In
mastocytosis, cognitive complaints call for complex neuropsychological assessment. Mild-moderate cognitive impairment
and depression constitute two specific but somewhat independent syndromes in mastocytosis. These results suggest
differential effects of mast-cell activity in the brain, on systems involved in emotionality and in cognition.
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Introduction
Mastocytosis is a rare and heterogeneous disease characterised
by accumulation of mast cells in one or several organs [1–3].
Based on organ dysfunction, systemic mastocytosis is divided
into indolent (.90% of cases) and aggressive forms [3,4].
Although in its indolent form mastocytosis is not a life
threatening disease, deregulated mast cells activation and
degranulation lead to the liberation of a panel of mediators
(such as serotonin, histamine, tryptase, heparin, substance P,
interleukins (IL8, IL4, IL10), TNF alpha…). Patients suffer from
various clinical symptoms related to mast-cell degranulation
and/or infiltration. These symptoms can be chronic (pruritus,
urticaria pigmentosa, headache, articular and muscular pain,
memory loss, attention impairment, depression) or paroxysmal
(Flush, anaphylactic like episodes, syncope) [5]. Chronic
symptoms of mastocytosis can be especially disabling and can
significantly affect patients in their personal, social and
professional life domains [6]. In this study, we report an
assessment of chronic memory and attention impairment in
mastocytosis and we explore the interrelationships with depres-
sion, age, education level, treatment and forms of the disease.
Cognitive complaints (memory and attention disturbances) are
common in mastocytosis and in our recent work 38% of patients
reported to feel concerned by these symptoms [6]. To date, only
the study of Rogers and collaborators has evaluated cognitive
impairments in 10 patients diagnosed with systemic mastocytosis
by using a valid psychometric measure of memory function [7].
These authors brought for the first time evidence for memory and
attention impairment in 70% of their sample of patients with
systemic mastocytosis. They suggested that mast cells deregulation
impact memory function through mediators released including
histamine. Other neuropsychiatric symptoms such as depression
are also present with high frequency in mastocytosis. The
prevalence of depression was estimated 40%, 70% and 64%
according to methods and cut offs used for investigation [6–8].
While prevalence and features of depression in mastocytosis has
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39468been recently well reported, cognitive (attention/memory) impair-
ment still remains to be described.
Among neuropsychological symptoms coinciding with cognitive
impairment, depression is the most frequent [9]. Although
depression and cognitive impairment are common co-morbidities,
the nature of this relationship and possible prognostic role of
depression is still under debate [10–13]. In mastocytosis, cognitive
impairment seems to be very frequent and since depression is a
common symptom among our patients, it is critical to investigate
both of these issues. In this work, we report an assessment of
cognitive impairment (memory and attention) in a large sample of
patients with mastocytosis (n=57). In addition, we have investi-
gated the relationship between depression, age, education, forms
of the disease, treatment and cognitive impairment. We provide
substantial evidence for high prevalence of cognitive impairment
and we strongly suggest that further refinement of the assessment
of memory and attention impairment in mastocytosis is needed.
Results
Subjective Complaints and Objective Cognitive
Impairment are Frequent in Mastocytosis
In our sample (n=57), 74% (n=42) of patients reported a
subjective complaint of cognitive impairment. Cognitive impair-
ment (scores #85) concerned 38.6% of patients (n=22). In this
group, the mean (M) age was 42.31 (range=20–66; standard
deviation (SD) = 12.08), 18 patients were under 53 years of age
and only one was older than 65 years; 77% were women,. The
education level was high (36% (n=8) attended at least a first
degree of graduation and 32% (n=7) had a Master or PhD
degree). Depression symptoms (Ham-D17$12) were present in
68% (n=15) of patients (M=15.18, range=0–35; SD=9.09), 14
were taking an antihistaminic treatment, 1 patient was treated by
imatinib, 5 were not taking any treatment, 3 were taking other
symptomatic treatments (cromoglycates and/or biphosphanates)
and 17 were taking psychotropic drugs including anxiolytic and
antidepressants.
Memory and attention impairments in mastocytosis are usually slight or
moderate and are characterized by immediate auditory and working memory
disabling.
Among our impaired patients (n=22), the prevalence of slight
(scores 85280) and moderate (scores 79271) cognitive impair-
ment was 86.3% (n=19). Severe impairment concerned only a
minority of patients (n=3). Figure 1 displays the features of
cognitive impairment for each of the 22 diagnosed mastocytosis
patients. Working memory (attention) impairment was the most
frequent with 73% (n=16) cases followed by auditory immediate
memory impairment (41% (n=9)). Auditory delayed memory and
visual memory impairments concerned 31.8% (n=7) of patients
and appeared only in the context of auditory immediate and/or
working memory disturbances (except for one patient). Patients
presenting delayed memory impairment were significantly more
impaired in attention (working memory) than patients without
such impairment (p=0.044) and presented more severe cognitive
impairment (p=0.012).
Cognitive Impairment was Unrelated to Age, Education,
forms of the Disease and Treatment in our Sample
Age did not distinguish our patients with respect to the presence
of cognitive impairment (M=42.31; S.D.=12.08 vs M=47.22;
S.D.=11.34; p=0.134) but patients with severe impairment were
significantly younger when compared to patients with slight or
moderate impairment (M=26; SD=7.21 vs M=45; SD=10.64;
p=0.022). We found no significant correlation between the
education level and the cognitive impairment (presence/severity
(r=20.179; p=0.182/r=0.181; p=0.178, respectively). The
mastocytosis clinical subcategories did not significantly correlate
with cognitive impairment presence/severity (r=0.218;
p=0.104/r=0.227; p=0.089 respectively). The percentage of
patients with an antihistaminic treatment was not significantly
different between patients with/without cognitive impairment
(63.6% (14/22) vs. 74.3% (26/35)) and there was no significant
correlation between the treatments used and the cognitive
impairment (ps $0.148). Among impaired patients, 7 were taking
psychotropic drugs and we found no correlation between these two
issues (r=0.035; p=0.799). Similar results were obtained with
subjective complaints (ps $0.070).
Depression is not Related to the Presence or the Severity
of Cognitive Impairment but Depressed Patients
Presented Lower Scores in Delayed Visual Memory
Patients with/without cognitive impairment did not distinguish
significantly neither in percentage of patients presenting depres-
sion symptoms (Ham-D17$12) (68.2% (15/22) vs. 51.4% (18/35);
p=0.220) nor in depression level (M=15.18; SD=9.09 vs.
M=12.48; SD=6.59; p=0.236) (Figure 2). No significant
correlation was found between depression (scores/presence) and
the severity of cognitive impairment (r=0.226; p=0.092/
r=0.228; p=0.088 respectively). In the impaired group (n=22),
depressed patients displayed slightly lower scores in delayed visual
memory (M=95.13; SD=12.74 vs. M=114.57; SD=11.41;
p=0.003) but no significant difference was found for visual
immediate memory (M=112.14; SD=7.73 vs. M=99.44;
SD=15.7; p=0.060), auditory memory (delayed: M=96.71;
SD=8.99 vs. M=91.46; SD=14.06; p=0.379; immediate:
M=93.28; SD=10.27 vs. M=88.44; SD=16.87; p=0.420)
and working memory (M=85.42; SD=8.20 vs. M=85.06;
SD=8.56; p=0.926).
Discussion
In this study, we show in a cohort of 57 patients that cognitive
impairment is highly prevalent (38.6%) in mastocytosis. Distur-
bances in attention (working memory) and auditory immediate
memory appeared as the most typical manifestations of cognitive
impairment in these patients. These cognitive impairments were
not related to depression, age, education level, or mastocytosis
clinical subcategories. Furthermore, no correlation was found
between cognitive impairment and antihistaminic intake, which is
in line with data suggesting that although histamine seems to have
a modulator effect in some mnemonic systems its exact function in
memory is still controversial [14].
The prevalence of memory impairment in our sample was high
but not as suggested by Rogers and collaborators (70% in a sample
of 10 patients) [7]. Although we used the same instrument for
diagnosing memory impairment, our study concerned a larger
sample, which reduces the risk of selection bias and ensures more
inter-variability. Our study provide evidence that the prevalence of
memory impairment in mastocytosis is unrelated to age or
education level (mean age of 42 years old and high education
(32%) in the impaired group). In addition, the prevalence of
cognitive impairment in our sample was significantly higher than
in younger populations (45 to 59 years old) suffering from chronic
somatic disease like diabetes or in elderly populations ($65 years)
in which prevalence of cognitive impairment-no dementia (CIND)
is around 15%–40% [15–20]. Interestingly, the prevalence of this
manifestation in our sample is similar than the one observed in
multiple sclerosis, an inflammatory disease involving mast cells in
Cognitive Impairment in Mastocytosis
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40% and 60% [21–23]. Furthermore, as reported above, although
the rate of depression is high in our sample, we found no
significant difference in the percentage of depressed patients with
and without cognitive impairment (memory/attention (working
memory) and no correlations between these two issues. Therefore,
we could conclude that in mastocytosis patients cognitive
impairment is not related to depression but rather to abnormal
number and/or activation of mast cells. An hypothesis for the lack
of correlation between cognitive symptoms and depression would
be that specific mediators/cytokines released by deregulated mast
cells (such as TNF-a or interleukin-6) would be required to
provoke depressive symptoms while a broad range of mediators
could impair cognitive process [24–26].
Only 7 patients were concerned with impairment in delayed
memory. They appeared to be particularly impaired in working
memory and 3 patients (significantly younger than the others)
displayed severe cognitive impairment in this group. These results
are in line with previous research in memory function suggesting
that worse deficits in working memory can lead to severe disability
as it can affect short and possibly long term memory domains [27].
Interestingly, the three patients displaying severe impairment
where all young women (20, 24 and 34 years old). According to
their medical records they had disorders of menstrual cycle
including amenorrhea (without pregnancy, excessive exercise or
anorexia), which was not a regular symptom among the other
women patients in our sample and in mastocytosis in general.
These three patients were also concerned with visual memory
impairment, which affected exclusively women (5 patients
concerned) in our sample. These observations could suggest that
an involvement of mast cells in neuroendocrine regulation through
acceleration of Gonadotropin-releasing hormone (GnRH) with
influence in cognition could concern female patients with
mastocytosis. This hypothesis is supported by several reports
showing that brain mast cells store and secrete GnRH and that
GnRH II, abundant in hippocampus and amygdales of primates
Figure 1. Features of cognitive impairment in mastocytosis. In the ordinate axis each line represents a patient. In the abscissa axis the severity
of the cognitive impairment is represented for each column (1: slight; 2: moderate; 3: severe). Columns displays features of cognitive impairment
observed (A: auditory; V: visual; I: immediate; D: delayed; WM: working memory). Black marks gives the feature and the severity of cognitive
impairment for each patient. Among the 22 patients WM impairment as the most frequent concerning 16 patients (10 with WM alone and 6
associated to auditory and/or visual impairment. In our sample (n=57), 22 patients (38.6%) were diagnosed with cognitive impairment. 12 patients
(59.1%) have slight impairment; 7 (27.3%) have moderate impairment and severe impairment affected 3 (13.6%) patients.
doi:10.1371/journal.pone.0039468.g001
Figure 2. Cognitive impaired patients are no more depressed
than patients without cognitive impairment. We performed an
unpaired t-test to compare depression scores of patients with and
without cognitive impairment. In the group of patients diagnosed with
cognitive impairment mean depression score was 15.8 (SD=9.09). In
the group without cognitive impairment diagnosis the mean depres-
sion score was 12.48 (SD=6.59).The analysis showed no significant
difference between the groups (t=1.296; p=0.200). CI: cognitive
impairment; ns: not significant.
doi:10.1371/journal.pone.0039468.g002
Cognitive Impairment in Mastocytosis
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39468and humans, has effects in cognition and particularly in visual
memory performance in young women [28–32].
In the brain, mast cells are present in diencephalon, especially in
hypothalamus, which is implicated in both emotion and cognition
systems [33–35]. The implication of these immune cells in
modulation of anxiety-like behaviour has been recently demon-
strated in mice [36]. In human, several reports have suggested the
implication of mast cells in anxious-depressive symptoms, in
autistic spectrum disorders and in neurological diseases as
Alzheimer and multiple sclerosis [8,37–39]. Moreover, degranu-
lation of brain mast cells has been linked to hypothalamic-
pituitary-adrenal (HPA) responses via histamine release [40,41].
Mast cells have also been shown to synthesise Corticotropin-
Releasing Hormone (CRH) and to be activated by CRH [42,43].
In addition, hyperactivation of HPA responses has been related to
cognitive processes in pathological situations such as type 2
diabetes, multiple sclerosis and Alzheimer disease [44–46].
Altogether, these data suggest that mast cells are implicated in
neuroimmunoendocrine responses. Therefore, alteration of the
number or abnormal activation of these cells could potentially
affect cognitive and emotional systems. In mastocytosis, several
symptoms can be exacerbated by stress and a hyperactivation of
HPA axis in patients presenting cognitive impairment is not
excluded. Further research would be necessary to investigate this
hypothesis.
There are few limitations to the current study. Even though the
Wechsler Memory Scale is used in many studies and provides valid
measures of memory functioning, a possible limitation to the
results is the use of only one instrument to evaluate these
impairments. Future research of memory impairment in masto-
cytosis should enlarge the panel of instruments used and include
evaluation of executive functions. In addition, our study provided
only cross-sectional data. A follow-up research will be necessary to
investigate the causes of occurrence, and the evolution of these
impairments. Nevertheless, this was the first description of
memory and attention impairment in mastocytosis in a large
sample of patients. We provided substantial evidence for high
prevalence of these symptoms among these patients. Attention
(working memory) and auditory immediate memory disturbances
where identified as the most typical manifestations of cognitive
impairment related to mastocytosis. Furthermore, we have shown
that there was no significant relation between depression and these
symptoms. Our results point to the need for further refinement of
the assessment of memory and attention impairment in mastocy-
tosis in a more systematic way. New pharmacological interventions
through inhibition of mast cell degranulation by tyrosine kynase
inhibitors (such as masitinib) could be used to treat cognitive
impairment in these patients. This strategy has been shown to
decrease mast cell degranulation related to symptoms in masto-
cytosis as well as cognitive impairment in Alzheimer disease.
Another strategy would be the reduction of hippocampal
neuroprotective kynurenic acid (KYNA) levels as proposed by
recent studies in the treatment of Alzheimer disease [8,47–50].
In conclusion, by evaluating cognitive functions in mastocyotsis
our data provide evidences for the role of mast cells in brain
functions. Targeting of mast cells could open new avenues in the
treatment of neurological and psychiatric disorders.
Methods
Sample Description (Table 1)
Table 1 displays our patient’s characteristics. Fifty seven
consecutive patients (15 men/42 women) with mastocytosis
diagnosis as defined by the WHO criteria [3] were evaluated
between 2008 and 2011. Mastocytosis subcategories comprised
indolent forms (cutaneous mastocytosis (n=12), systemic masto-
cytosis (n=41)) and aggressive mastocytosis (n=4). Mean age on
study was 45 years (range=20–75); S.D.=11.78) and only 3
patients were 65 years or older. Education level was high (Master
or PhD degree) in 40% (n=23). Most of patients (70%) were
taking an antihistaminic treatment as symptomatic treatment and
58% (n=33) were depressed (M=13.52; range=0–35;
S.D.=7.69).
The study was approved by Necker hospital ethical committee,
and carried out according to the Helsinki convention. Each patient
was informed about the study and provided written consent.
Subjective and Objective Memory Impairment
Subjective memory complaints were measured by asking
patients if they were concerned by memory difficulties (i.e.
forgetfulness, difficulties in finding words, in remembering names,
in concentrating and distractibility). Objective memory impair-
ment was evaluated using the third edition of the Clinical Memory
Scale of Wechsler [51]. This scale provides a standardised measure
of important aspects of memory validated in French community.
This instrument gives immediate and delayed scores for auditory
and visual memory as well as scores for working memory that
corresponds to attention capacities. Abnormal scores are consid-
ered from 21 standard deviation (SD) of the mean (M) T scores
(100). Thus a score between 85 and 80 is reflecting a slight
abnormality in memory function, whereas a score #70 (22 SD)
reflects a severe memory dysfunction. Objective cognitive impair-
ment was diagnosed if the score was #85 in at least one of the
memory dimensions evaluated as it is usually done in practice.
Table 1. Sample description.
N=57 N (%) M, range (S.D.)
Age 45, 20–75 (11.78)
Women 42 (74)
Men 15 (26)
Depression 13.52, 0–35 (7.69)
Depressed
(Ham-D17 score $12)
33(58)
Forms of mastocytosis
Indolent mastocytosis 53 (93)
Aggressive mastocytosis 4 (7)
Treatments
Antihistaminic 1 24 (42)
Antihistaminic 1 and 2 16 (28)
Glyvec 1 (2)
none 11 (19)
Others (cromoglycates and/or
biophosphanates)
5(9)
Psychotropic (anxiolytic/
antidepressants
17 (30)
Education
Primary (n=1)/Secondary 13(23)
Bachelor’s degree 21(37)
Master or PhD degree 23(40)
aGraduation level. M (mean); S.D. (standard deviation); N: number of patients.
doi:10.1371/journal.pone.0039468.t001
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Depression symptoms were measured with the 17 items
Hamilton Depression Ranting Scale questionnaire (Ham-D17)
[52]. Items were scored after a clinical interview focused on
depression symptoms. The cut-off used to define presence of
depression symptoms was Ham-D17$12.
Procedures
All patients were evaluated by the same licensed psychologist
(DSM) in the French Reference Centre of Mastocytosis in Paris.
An interval of 20 minutes was made between the end of part 1
(immediate recall) and the start of part 2 (delayed recall) of the
memory test and patients were than screened for depression
symptoms and asked about their memory complaints. Working
memory was evaluated at the end of the part 1.
Statistical Analysis
SPSS version 17.0 (IBM SPSS Inc., Chicago, IL, USA) was used
for descriptive and correlation analysis in relation to forms of
mastocytosis and education level. Mann Whitney test for
nonparametric data and unpaired t test used to compare groups
in relation to cognitive impairment, depression, age, and treatment
were performed using GraphPad Prism software version 5.01
(GraphPad Software Inc., San Diego, CA).
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